Current Management of Castration-Resistant Prostate Cancer (CRPC)

A better understanding of the molecular biology of castration-resistant prostate cancer has led to a dramatic paradigm shift in the treatment of patients with metastatic disease where the androgen receptor becomes a central therapeutic target in the disease. Novel adrenal and engineered androgen receptor inhibitors have become the most promising agents in the disease. Novel immune therapies have been shown to improve survival in selected patients with castration-resistant disease despite the inability to impact traditional markers of response. Similarly, second-line chemotherapy with Cabazitaxel has demonstrated clinical benefit and is now the standard of care in taxane-refractory patients. These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.